The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Role for DNA Damage Signaling in Pulmonary Arterial Hypertension
Abstract
Background—: Pulmonary arterial hypertension (PAH) is associated with sustained inflammation known to promote DNA damage. Despite these unfavorable environmental conditions, PAH pulmonary arterial smooth muscle cells (PASMCs) exhibit, in contrast to healthy PASMCs, a pro-proliferative and anti-apoptotic phenotype, sustained in time by the activation of miR-204, nuclear factor of activated T cells, and hypoxia-inducible factor 1-α. We hypothesized that PAH-PASMCs have increased the activation of poly(ADP-ribose) polymerase-1 (PARP-1), a critical enzyme implicated in DNA repair, allowing proliferation despite the presence of DNA-damaging insults, eventually leading to PAH. Methods and Results—: Human PAH distal pulmonary arteries and cultured PAH-PASMCs exhibit increased DNA damage markers (53BP1 and γ-H2AX) and an overexpression of PARP-1 (immunoblot and activity assay), in comparison with healthy tissues/cells. Healthy PASMCs treated with a clinically relevant dose of tumor necrosis factor-α harbored a similar phenotype, suggesting that inflammation induces DNA damage and PARP-1 activation in PAH. We also showed that PARP-1 activation accounts for miR-204 downregulation (quantitative reverse transcription polymerase chain reaction) and the subsequent activation of the transcription factors nuclear factor of activated T cells and hypoxia-inducible factor 1-α in PAH-PASMCs, previously shown to be critical for PAH in several models. These effects resulted in PASMC proliferation (Ki67, proliferating cell nuclear antigen, and WST1 assays) and resistance to apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling and Annexin V assays). In vivo, the clinically available PARP inhibitor ABT-888 reversed PAH in 2 experimental rat models (Sugen/hypoxia and monocrotaline). Conclusions—: These results show for the first time that the DNA damage/PARP-1 signaling pathway is important for PAH development and provide a new therapeutic target for this deadly disease with high translational potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070
Bonnet, S., Archer, S. L., Allalunis-Turner, J., Haromy, A., Beaulieu, C., Thompson, R., Lee, C. T., Lopaschuk, G. D., Puttagunta, L., Bonnet, S., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.10.020 · Cited by 1,530
Self-citationPARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Cardiovascular Complications of Cancer Therapy: Diagnosis, Pathogenesis, and Management
Yeh, E. T. H., Tong, A. T., Lenihan, D. J., Yusuf, S. W., Swafford, J., Champion, C., Durand, J.-B., Gibbs, H., Zafarmand, A. A., & Ewer, M. S. (2004) · Circulation · doi:10.1161/01.cir.0000133187.74800.b9 · Cited by 843
Soon, E., Holmes, A. M., Treacy, C. M., Doughty, N. J., Southgate, L., Machado, R. D., Trembath, R. C., Jennings, S., Barker, L., Nicklin, P., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.933762 · Cited by 802
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
Luo, X., & Kraus, W. L. (2012) · Genes & Development · doi:10.1101/gad.183509.111 · Cited by 725
Bonnet, S., Michelakis, E. D., Porter, C. J., Andrade-Navarro, M. A., Thébaud, B., Bonnet, S., Haromy, A., Harry, G., Moudgil, R., McMurtry, M. S., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.609008 · Cited by 590
Self-citationRole for miR-204 in human pulmonary arterial hypertension
Courboulin, A., Paulin, R., Giguère, N. J., Saksouk, N., Perreault, T., Meloche, J., Paquet, E. R., Biardel, S., Provencher, S., Côté, J., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101812 · Cited by 523
Self-citationTuder, R. M., Chacon, M., Alger, L., Wang, J., Taraseviciene‐Stewart, L., Kasahara, Y., Cool, C. D., Bishop, A. E., Geraci, M., Semenza, G. L., et al. (2001) · The Journal of Pathology · doi:10.1002/path.953 · Cited by 500
Cited by
Cellular senescence impairs the reversibility of pulmonary arterial hypertension
van der Feen, D. E., Bossers, G. P. L., Hagdorn, Q. A. J., Moonen, J.-R., Kurakula, K., Szulcek, R., Chappell, J., Vallania, F., Donato, M., Kok, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4974 · Cited by 150
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born, E., Lipskaia, L., Breau, M., Houssaini, A., Beaulieu, D., Marcos, E., Pierre, R., Do Cruzeiro, M., Lefevre, M., Derumeaux, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.058794 · Cited by 148
Metadata
- Authors
- Meloche, J., Pflieger, A., Vaillancourt, M., Paulin, R., Potus, F., Zervopoulos, S., Graydon, C., Courboulin, A., Breuils-Bonnet, S., Tremblay, È., Couture, C., Michelakis, E. D., Provencher, S., & Bonnet, S.
- Venue
- Circulation
- Published
- 2014-02-18
- Volume
- 129
- Issue
- 7
- Pages
- 786-797
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2076168873
- Cited by
- 254
- References
- 51
- FWCI
- 11.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.